Faeth Therapeutics, Inc. Earnings
The next earnings date for Faeth Therapeutics, Inc. is November 13, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of Faeth Therapeutics, Inc. Earnings
| 11/13/2026 | $-0.66 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Faeth Therapeutics, Inc. Earnings: Historical
| 08/04/2026 | Before Market | $-2.84 | -158.18% |
| 05/15/2026 | Before Market | $-131.45 | -21,101.61% |
| 03/30/2026 | --- | $-3.74 | 22.25% |
| 11/14/2025 | Before Market | $-3.62 | 11.92% |
| 08/05/2025 | Before Market | $-3.91 | 21.80% |
| 05/06/2025 | --- | $-5.45 | --- |
| 03/28/2025 | Before Market | $-5.46 | 5.86% |
| 11/14/2024 | Before Market | $-5.80 | 9.09% |
| 08/06/2024 | Before Market | $-5.60 | -2.00% |
| 05/09/2024 | --- | $-6.38 | --- |
More About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
“Faeth Therapeutics, Inc. Earnings” Can Refer to the Faeth Therapeutics, Inc. Earnings Date
Some people say “Faeth Therapeutics, Inc. earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Faeth Therapeutics, Inc. position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Faeth Therapeutics, Inc. Stock on the Earnings Date
If you own Faeth Therapeutics, Inc. stock (FTH) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Faeth Therapeutics, Inc. might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Faeth Therapeutics, Inc. shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More Faeth Therapeutics, Inc. Earnings
You can contact us any time if you would like to ask questions about Faeth Therapeutics, Inc. earnings or anything else related to the stock market.